MILAN (Reuters) - The Barilla family, which owns the pasta maker of the same name, has donated $500,000 to U.S. non-profit association “The Cure Alliance” to fund research on a COVID-19 therapy based on stem cells, the group said on Monday.
The clinical trial for the cure, which is being developed by a group of international scientists led by Italian professor Camillo Ricordi, has already received approval from the U.S. Food and Drug Administration, Barilla said.
A 24-patient clinical trial will be carried out in Miami to assess the efficacy of the therapy aimed at blocking the life-threatening lung inflammation that accompanies severe cases of the disease triggered by the coronavirus.
The money adds to a previous 2 million euro ($2.19 million) donation made last month by the company to health institutions in Italy to fight the coronavirus outbreak in the company’s home country.
Reporting by Francesca Landini. Editing by Jane Merriman
Our Standards: The Thomson Reuters Trust Principles.